Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa

BACKGROUND: Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa. We assessed the cost-effectiveness of four sofosbuvir-based regimens recommended by the World Health Or...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyer, Sylvie, Baudoin, Maël, Nishimwe, Marie Libérée, Santos, Melina, Lemoine, Maud, Maradan, Gwenaëlle, Sylla, Babacar, Kouanfack, Charles, Carrieri, Patrizia, Mourad, Abbas, Rouveau, Nicolas, Moh, Raoul, Seydi, Moussa, Attia, Alain, Woode, Maame Esi, Lacombe, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897946/
https://www.ncbi.nlm.nih.gov/pubmed/35248039
http://dx.doi.org/10.1186/s12913-021-07289-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897946/
https://www.ncbi.nlm.nih.gov/pubmed/35248039
http://dx.doi.org/10.1186/s12913-021-07289-0

Ejemplares similares